Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes.
Assessment of residual disease after neoadjuvant therapy for breast cancer is an ongoing challenge of breast imaging. This study evaluates the accuracy of a novel dedicated system for molecular breast imaging (MBI) composed of the new generation of cadmium zinc telluride detectors in assessing residual disease after neoadjuvant therapy in patients with breast cancer.



Clinical data, imaging, surgical, and pathological findings of 51 women with breast cancer undergoing neoadjuvant therapy were recorded. MBI findings were correlated with surgical pathology results. Accuracy of MBI in predicting complete pathological response and size of residual disease was assessed according to molecular subtypes.



The size of the largest focus of uptake on MBI correlated with the largest dimension measured on pathology (r = 0.55; P < .001). This correlation was stronger for triple negative and HER2/neu positive subtypes (r = 0.92 and 0.62, respectively). Sixteen patients (31%) had complete pathological response. The sensitivity and specificity of MBI for detecting residual disease were 83% (95% confidence interval [CI], 66-93) and 69% (95% CI, 42-88), respectively. For triple negative or HER2/neu positive disease the sensitivity and specificity were 88% (95% CI, 62-98) and 75% (95% CI, 43-93), respectively.



The accuracy of MBI in assessing residual disease after neoadjuvant treatment might be related to the molecular subtype. Accuracy is highest in the triple negative and HER2/neu positive subtypes.
Department of Surgery, Tel Aviv Sourasky Medical Center, and Sackler School of Medicine, Tel Aviv, Israel. Electronic address: tehillahm@tlvmc.gov.il.
Tehillah S
TS
Menes
Department of Radiology, Tel Aviv Sourasky Medical Center, and Sackler School of Medicine, Tel Aviv, Israel.
Orit
O
Golan
Department of Pathology, Tel Aviv Sourasky Medical Center, and Sackler School of Medicine, Tel Aviv, Israel.
Gilead
G
Vainer
Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center, and Sackler School of Medicine, Tel Aviv, Israel.
Hedva
H
Lerman
Department of Surgery, Tel Aviv Sourasky Medical Center, and Sackler School of Medicine, Tel Aviv, Israel.
Schlomo
S
Schneebaum
Department of Surgery, Tel Aviv Sourasky Medical Center, and Sackler School of Medicine, Tel Aviv, Israel.
Joseph
J
Klausner
Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center, and Sackler School of Medicine, Tel Aviv, Israel.
Einat
E
Even-Sapir
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001940:Breast / Q000000981:diagnostic imaging / Q000473:pathology; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008327:Mammography; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D018365:Neoplasm, Residual; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D064726:Triple Negative Breast Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000473:pathology; D016217:Ultrasonography, Mammary
D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C508053:ERBB2 protein, human
Breast cancer; Breast conserving surgery; Complete pathological response; Functional imaging